TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Travere Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Market Cap | $4.76B | $164.85M |
| Enterprise Value | $4.47B | $87.06M |
| PS Ratio | 8.05 | 3.60 |
| PB Ratio | 194.08 | 2.03 |
| P/OCF Ratio | 51.34 | 13.32 |
Enterprise value
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 7.55 | 2.43 |
| EV / EBITDA | 194.89 | 14.69 |
Income (trailing twelve months)
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Revenue | $591.33M | $57.94M |
| Gross Profit | $583.07M | $90.47M |
| Operating Income | -$40.46M | -$21.44M |
| Pretax Income | -$67.07M | -$14.45M |
| Net Income | -$43.46M | -$22.46M |
| EBITDA | $22.91M | -$16.91M |
| EPS (Diluted) | -$0.46 | -$0.83 |
Margins
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 98.6% | 52.3% |
| Operating Margin | -6.84% | -44.5% |
| Pretax Margin | -11.3% | -13.0% |
| Profit Margin | -7.35% | -39.2% |
| EBITDA Margin | 3.87% | -31.3% |
Returns
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -151.8% | -53.1% |
| Return on Assets (ROA) | -6.42% | -41.0% |
| Return on Capital Employed (ROCE) | -6.25% | -37.8% |
Growth
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 77.1% | 6.01% |
| Revenue Growth (3Y CAGR) | 64.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 19.9% | 6.42% |
Balance sheet
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $293.65M | $62.42M |
| Net Cash (Debt) | $293.65M | $15.68M |
| Net Cash Per Share | $3.12 | $0.66 |
| Equity (Book Value) | $24.52M | $48.79M |
| Book Value Per Share | $0.26 | $1.36 |
| Tangible Book Value | -$107.00M | $23.06M |
| Working Capital | $463.12M | $75.77M |
Financial position
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.05 | 3.30 |
| Quick Ratio | 2.46 | 2.39 |
| Interest Coverage | -4.27 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $92.70M | -$12.35M |
Efficiency
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.87 | 0.38 |
| Inventory Turnover | 0.21 | 2.67 |
| Revenue Per Employee | $1.19M | $398.96K |
| Profits Per Employee | -$87.45K | -$703.34K |
| Employee Count | 497 | 74 |
Dividends and yields
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -0.91% | -22.7% |
Shares
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 94,261,100 | 58,179,650 |
| Shares Change (YoY) | 11.8% | 11.1% |
| Shares Change (QoQ) | 1.92% | 0.54% |
| Float | 92,775,400 | 49,173,100 |
| Shares Held by Insiders | 1.58% | 11.6% |
| Shares Held by Institutions | 112.1% | 59.4% |
Taxes
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Income Tax | $605.00K | $91.50K |
Scores
| Measure | Travere Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.25 | -0.24 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -1.51 | -2.62 |
Calculated by StockData from Travere Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.